Scaling Cell and Gene Therapies
Cell and gene therapy developers know that while there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Innovative systems such as automation, for example, may help developers to track materials through the production process, minimize labor requirements, and reduce the risk of human error. Because scale up and scale out are significant to everyone in the cell and gene sector, we’ve curated insightful editorial that addresses the most important aspects of scalability in the cell and gene therapy space.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.